Cernostics

About

Cernostics is a life science company developing new molecular diagnostic tests to treat cancer.

Danville,Pennsylvania,United States
11 - 50

Highlights

Details

Last Funding Type: Debt Financing
Industries: Biotechnology,Health Diagnostics,Life Science,Medical Device
Founded date: Jan 1, 2008
Number Of Employee: 11 - 50
Operating Status: Active
Legal Name: Cernostics, Inc
Also Known As: Cernostics Pathology Inc.

Cernostics is a life science company developing new molecular diagnostic tests for the fight against cancer. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple cell types, not merely tumor cells.

Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

12

$21.26M

Cernostics has raised a total of $21.26M in funding over 2 rounds. Their latest funding was raised on Aug 13, 2021 from a Series Unknown round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Aug 13, 2021	Series Unknown	$5.98M	—	—	—	Detail
Mar 21, 2018	Series A	$2.50M	1	Illumina Ventures	—	Detail
Aug 31, 2016	Series Unknown	$5M	2	UPMC	—	Detail
Jun 8, 2015	Series Unknown	$1.96M	1	Ben Franklin Technology Partners of Northeastern Pennsylvania	—	Detail
Feb 20, 2014	Series Unknown	—	1	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

4

7

Cernostics is funded by 7 investors. Illumina Ventures and UPMC are the most recent investors.

Investor Name	Lead Investor	Funding Round
Illumina Ventures	Yes	Series A
UPMC	Yes	Series Unknown
Ben Franklin Technology Partners of Northeastern Pennsylvania	Yes	Series Unknown
Novitas Capital	—	Series Unknown
Geisinger	—	Series B
Pittsburgh Life Sciences Greenhouse	—	Series B
Geisinger Ventures	—	Series A